Aldimines Or Ketimines Which Contain A Benzene Ring (i.e., Rc=n Wherein R Is C Or H) Patents (Class 514/641)
  • Patent number: 9481677
    Abstract: This invention is directed to biaryl ether sulfonamides, or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
    Type: Grant
    Filed: October 30, 2012
    Date of Patent: November 1, 2016
    Assignee: XENON PHARMACEUTICALS INC.
    Inventors: Shifeng Liu, Thilo Focken, Navjot Chahal, Zaihui Zhang, Renata Marcella Oballa, Julia Fonarev
  • Patent number: 9365578
    Abstract: This invention is directed to biaryl ether sulfonamides, or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
    Type: Grant
    Filed: October 30, 2012
    Date of Patent: June 14, 2016
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Shifeng Liu, Thilo Focken, Navjot Chahal, Zaihui Zhang, Renata Marcella Oballa, Julia Fonarev
  • Patent number: 9353121
    Abstract: The invention provides methods of inhibiting the growth or metastasis of a cancer in a mammal by inhibiting a Ral GTPase in the mammal. The invention also provides small molecule inhibitors of Ral GTPases useful in the methods of the invention and pharmaceutical compositions containing the therapeutically effective compounds of the invention, and methods of using the same.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: May 31, 2016
    Inventors: Dan Theodorescu, Michael Fitzpatrick Wempe, David Ross, Samy Meroueh, Martin A. Schwartz, Phillip Reigan
  • Patent number: 9297032
    Abstract: The invention provides methods for increasing the recoverability of taggants from an object. The methods include the steps of incorporating a taggant into a solution; mixing the solution including the taggant with a perturbant to form a first perturbant taggant solution; mixing the first perturbant taggant solution with a polymer to form a second perturbant taggant polymer solution; and applying the second perturbant taggant polymer solution to at least a portion of the object to form a taggant-coated object. Methods for authentication of a taggant marked object are also provided.
    Type: Grant
    Filed: October 10, 2012
    Date of Patent: March 29, 2016
    Assignee: APDN (B.V.I.) Inc.
    Inventors: Lawrence Jung, MingHwa Benjamin Liang, James A. Hayward
  • Patent number: 9181200
    Abstract: Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: November 10, 2015
    Assignee: Myokardia, Inc.
    Inventors: Johan Oslob, Robert Anderson, Danielle Aubele, Marc Evanchik, Jonathan Charles Fox, Brian Kane, Puping Lu, Robert McDowell, Hector Rodriguez, Yonghong Song, Arvinder Sran
  • Patent number: 9115122
    Abstract: A compound, having the formula A-1: Wherein R1 and R2 are defined herein. Methods of using the compound and compositions containing the compound are provided.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: August 25, 2015
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Paul S. Shapiro, Alexander D. MacKerell, Jr., Steven Fletcher
  • Patent number: 9056111
    Abstract: The present invention provides pyrazolo[1,5-a]pyrimidine compounds which inhibit cancer-associated transporter proteins, methods of treating or preventing the onset of a cancer-associated transporter protein-mediated disease by administering such compounds, and pharmaceutical compositions comprising such compounds. In one embodiment, the invention provides pyrazolo[1,5-a]pyrimidine efflux inhibitors that are selective toward ABCG2 over ABCB1. Compounds and compositions according to the present invention may be used to treat cancer, including drug resistant (DR) and multiple drug resistant (MDR) cancers.
    Type: Grant
    Filed: September 19, 2012
    Date of Patent: June 16, 2015
    Assignees: STC.UNM, UNIVERSITY OF KANSAS
    Inventors: Richard Smith Larson, Larry A. Sklar, Bruce S. Edwards, Juan Jacob Strouse, Irena Ivnitski-Steele, Hadya M. Khawaja, Jerec Warren Ricci, Jeffrey Aube, Jennifer Elizabeth Golden, Tuanli Yao, Warren S. Weiner, Chad E. Schroeder
  • Patent number: 8993634
    Abstract: This application describes pharmaceutical compositions, kits, and methods for inhibiting cell proliferative disorders, especially those disorders characterized by overactivity and/or inappropriate activity of a receptor tyrosine kinase, including Her2 related cancers, and methods for imaging an Her-2 expressing tumor.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: March 31, 2015
    Assignee: The Trustees Of The University Of Pennsylvania
    Inventors: Mark I. Greene, Ramachandran Murali, Hongtao Zhang
  • Publication number: 20150010469
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer, stereoisomer or deuterated analogue thereof, wherein X, R, R1, R2, R3, R4, M1, M2, L1, L2, J1, J2, a1, a2, b1 and b2 are as defined herein, are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
    Type: Application
    Filed: July 3, 2014
    Publication date: January 8, 2015
    Applicants: British Columbia Cancer Agency Branch, University of British Columbia
    Inventors: Raymond John Andersen, Javier Garcia Fernandez, Marianne Dorothy Sadar
  • Publication number: 20140314882
    Abstract: Combinations of compounds are provided that produce a synergistic effect when administered.
    Type: Application
    Filed: June 27, 2014
    Publication date: October 23, 2014
    Inventors: Frederick P. ROTH, Murat COKOL, Hon Nian CHUA
  • Patent number: 8853452
    Abstract: Compounds and their syntheses are disclosed herein. Compositions and pharmaceutical compositions comprising a compound are also described, and include compositions also comprising liposomes. Methods for the treatment of cancer in animals comprising administering a compound or a composition comprising a compound are also described.
    Type: Grant
    Filed: February 9, 2010
    Date of Patent: October 7, 2014
    Assignee: The Administrators of the Tulane Educational Fund
    Inventors: Barbara S. Beckman, Maryam Foroozesh, Jiawang Liu
  • Publication number: 20140249193
    Abstract: The present invention provides compounds that modulate protein translocation in mitochondria, compositions thereof, and methods of identifying, making and using these.
    Type: Application
    Filed: April 12, 2012
    Publication date: September 4, 2014
    Applicant: The Regents of the University of California
    Inventors: Carla M. Koehler, Samuel A. Hasson, Kiyoko Miyata, Micheal A. Teitell, Deepa Dabir
  • Patent number: 8802120
    Abstract: Bioactive agrichemical concentrates and compositions having improved bioactivity comprising combinations of acid solutions and conventional bioactive agrichemical actives or formulations.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: August 12, 2014
    Assignee: Sciessent LLC
    Inventor: Joseph J. Crudden
  • Publication number: 20140221473
    Abstract: Embodiments of the present disclosure provide compositions including ketamine analogues, salts, and disalts, pharmaceutical compositions including ketamine analogues, salts, or disalts, methods of treatment of a condition or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.
    Type: Application
    Filed: June 29, 2012
    Publication date: August 7, 2014
    Inventors: Jahanshah Amin, Kirpal S. Bisht, Meghanath Gali
  • Publication number: 20140193518
    Abstract: The invention relates to kinase inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating disorders, especially cancer.
    Type: Application
    Filed: December 28, 2012
    Publication date: July 10, 2014
    Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventor: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
  • Patent number: 8680155
    Abstract: Novel synthetic bis(benzylidene-benzenamine)disulfides and the preparation method are disclosed in the present invention. These compounds are afforded with the oxidizing reagent at low temperature and short time period via intra-molecular coupling reaction. In vitro experiments have been revealed that bis-disulfides are cytotoxic to cancer cells, especially human breast cancer cells MCF-7. Additionally, bis-disulfides arrest the cell cycle at sub-G1 phase and increase p38 phosphorylation to result in apoptosis. Bis-disulfides also inhibit growth of murine melanoma B16 cells but have no cytotoxicity to human fibroblasts. Bis-disulfides also can reduce murine melanoma size in the mouse model. The prepared compounds of the invention would be applicable in anticancer and anti-tumor therapies.
    Type: Grant
    Filed: July 26, 2011
    Date of Patent: March 25, 2014
    Assignee: Kaohsiung Medical University
    Inventors: Jeh-Jeng Wang, Wan-Ping Hu, Wei-Sheng Lo
  • Patent number: 8642660
    Abstract: A method for altering the lifespan of a eukaryotic organism. The method comprises the steps of providing a lifespan altering compound, and administering an effective amount of the compound to a eukaryotic organism, such that the lifespan of the organism is altered. In one embodiment, the compound is identified using the DeaD assay.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: February 4, 2014
    Assignee: The University of Rochester
    Inventor: David Scott Goldfarb
  • Publication number: 20140031376
    Abstract: The compound (I) or a salt thereof has an excellent controlling activity against pests. Then the compound (I) or a salt thereof is useful for an active ingredient of a pesticidal composition.
    Type: Application
    Filed: October 3, 2013
    Publication date: January 30, 2014
    Applicant: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Shigeyuki ITOH, Atsushi IWATA
  • Publication number: 20130345164
    Abstract: This invention concerns methods of identifying treatments for treating various disorders and related computer products and systems. Also disclosed are methods for treating cellular proliferative disorders and use of compounds identified for such treatment.
    Type: Application
    Filed: April 21, 2011
    Publication date: December 26, 2013
    Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
    Inventors: Alexei Vazquez, Darren Carpizo, Arnold Levine
  • Publication number: 20130310254
    Abstract: The present application relates to novel alpha, beta-unsaturated imines, to processes for their preparation, to their use for controlling animal pests including arthropods and in particular insects and to their use in the control of vectors.
    Type: Application
    Filed: November 24, 2011
    Publication date: November 21, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Stefan Werner, Ulrich Ebbinghaus-Kintscher, Sebastian Horstmann, Michael Maue, Hans-Georg Schwarz, Robert Velten, Arnd Voerste, Ulrich Görgens, Andreas Turberg
  • Publication number: 20130274283
    Abstract: Premature termination codons readthrough compounds, composition thereof, and methods of making and using the same are provided.
    Type: Application
    Filed: February 11, 2013
    Publication date: October 17, 2013
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Richard A. GATTI, Liutao DU, Robert DAMOISEAUX, Chih-Hung LAI, Michael JUNG, Jin-Mo KU, Carmen BERTONI
  • Publication number: 20130261146
    Abstract: A pharmaceutical composition for stimulating nitric oxide production in mammalian cells, the pharmaceutical composition including at least one compound selected from a group consisting of: 2,3-dihydroxypropyl oleate; bis(m-phenoxyphenyl) ether; 6-acetyl-5,6,6a,7-tetrahydro-4H-dibezo(de,g)quinoline; and (+)-N-(p-(2-methylbutoxy)benzylidene)-4-(2-methylbutyl)aniline.
    Type: Application
    Filed: December 9, 2010
    Publication date: October 3, 2013
    Applicant: The Research Foundation of State University of New York
    Inventors: George B. Stefano, Wei Zhu, Kirk Mantione, Richard M. Kream
  • Publication number: 20130190405
    Abstract: This application describes pharmaceutical compositions, kits, and methods for inhibiting cell proliferative disorders, especially those disorders characterized by overactivity and/or inappropriate activity of a receptor tyrosine kinase, including Her2 related cancers, and methods for imaging an Her-2 expressing tumor.
    Type: Application
    Filed: May 26, 2011
    Publication date: July 25, 2013
    Applicant: The Trustees of The University of Pennsylvania
    Inventors: Mark I. Greene, Ramachandran Murali, Hongtao Zhang
  • Publication number: 20130150392
    Abstract: The compound (I) or a salt thereof has an excellent controlling activity against pests. Then the compound (I) or a salt thereof is useful for an active ingredient of a pesticidal composition.
    Type: Application
    Filed: February 8, 2013
    Publication date: June 13, 2013
    Applicant: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventor: SUMITOMO CHEMICAL COMPANY, LIMITED
  • Publication number: 20130085137
    Abstract: The invention includes a method of treating a mammal comprising topically applying an aqueous composition to a target site on the mammal, wherein the aqueous composition comprises: active ingredients comprising i) a cosmetic dye selected from a violet, blue or green dye, or combinations thereof, and ii) an enhancing ingredient, wherein the relative weight percentage of the cosmetic dye to the enhancing ingredient is about 1:2 to about 40:1, wherein the cosmetic dye interacts with keratinous material thereby i) substantially staining the target site and ii) inhibiting the active ingredients from significantly leaching from the target site.
    Type: Application
    Filed: September 21, 2012
    Publication date: April 4, 2013
    Applicant: Hydromer, Inc.
    Inventor: Hydromer, Inc.
  • Publication number: 20130065850
    Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.
    Type: Application
    Filed: April 3, 2012
    Publication date: March 14, 2013
    Applicant: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: Josh MUNGER, Bryson BENNETT, Thomas SHENK, Joshua RABINOWITZ
  • Patent number: 8383682
    Abstract: A composition comprises surface-modified nanoparticles of at least one amphoteric metal oxide or oxyhydroxide. The nanoparticles bear, on at least a portion of their surfaces, a surface modification comprising (i) at least one surface modifier selected from lactate, thiolactate, and mixtures thereof, and (ii) at least one surface modifier selected from halide, nitrate, acetate, carbonate, formate, propionate, sulfate, bromate, perchlorate, tribromoacetate, trichloroacetate, trifluoroacetate, carboxylate comprising from one to about four alkyleneoxy moieties, chlorate, and mixtures thereof.
    Type: Grant
    Filed: December 16, 2008
    Date of Patent: February 26, 2013
    Assignee: 3M Innovative Properties Company
    Inventor: Timothy D. Dunbar
  • Publication number: 20130035284
    Abstract: The present invention concerns methods and compositions involving small molecule inhibitors for the treatment or prophylaxis of flavivirus infection, such as dengue virus and West Nile virus.
    Type: Application
    Filed: March 5, 2012
    Publication date: February 7, 2013
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Stanley J. Watowich, Suzanne M. Tomlinson, Scott Gilbertson
  • Publication number: 20120283249
    Abstract: The subject matter of the present invention is novel families of compounds which are aromatic amine, imine, aminoadamantane and benzodiazepine derivatives, medicaments comprising same and the use thereof as inhibitors of the toxic effects of toxins with intracellular activity, such as, for example, ricin, and of viruses that use the internalization pathway for infecting cells.
    Type: Application
    Filed: June 17, 2009
    Publication date: November 8, 2012
    Inventors: Roman Lopez, Séverine Hebbe, Daniel Gillet, Julien Barbier
  • Patent number: 8287893
    Abstract: Bioactive agrichemical concentrates and compositions having improved bioactivity comprising combinations of acid solutions and conventional bioactive agrichemical actives or formulations.
    Type: Grant
    Filed: May 19, 2008
    Date of Patent: October 16, 2012
    Assignee: Sciessent LLC
    Inventor: Joseph J. Crudden
  • Publication number: 20120190738
    Abstract: The present invention relates to compounds of general formula I for the treatment of malignancy by inhibition of PI3-Akt pathway and or induction of NO. The present invention also relates to the use of compound of general formula I for the treatment of malignancy by inhibition of PI3-Akt pathway and or induction of NO. The present invention further relates to a method of treating malignancy by inhibition of PI3-Akt pathway and or induction of NO by administration of compound or said composition to a mammal in need thereof.
    Type: Application
    Filed: January 12, 2010
    Publication date: July 26, 2012
    Inventors: Santu Bandyopadhyay, Bikas Chandra Pal, Jaisankar Parasuraman, Siddhartha Roy, Jayashree Bagchi Chakrabotry, Indrani Choudhury Mukherjee, Sanjit Kumar Mahato, Aditya Konar, Srabanti Rakshit, Labanya Mandal, Dipyaman Ganguly, Kausik Paul, Anirban Manna, Jayaraman Vinayagam, Churala Pal
  • Publication number: 20120178749
    Abstract: The present invention generally relates to compounds to treat viral infections and methods of their use. In particular, compounds of the present invention inhibit the activity of NS1 protein, thereby mitigating viral infection and, in particular, influenza virus infection. Accordingly, NS1 protein inhibitors and methods of treatment that employ such inhibitors are contemplated by the present invention.
    Type: Application
    Filed: February 21, 2012
    Publication date: July 12, 2012
    Inventors: Michael Roth, Beatriz Fontoura, Shuguang Wei, Neal Satterly
  • Publication number: 20120128667
    Abstract: The present invention relates to the treatment of cancer, e.g., ovarian cancer, breast cancer, pancreatic cancer or colon cancer, with pentamidine and (a) oxaliplatin, (b) gemcitabine, (c) taxol, (d) 5-fluorouracil or (e) CPT 11.
    Type: Application
    Filed: May 3, 2010
    Publication date: May 24, 2012
    Applicant: ONCOZYME PHARMA INC.
    Inventors: Terry Chow, Chiaoli Yeh, David Griller
  • Publication number: 20120128592
    Abstract: A compound for detecting an analyte using Surface Enhanced Raman Spectroscopy (SERS) and a method of forming the compound is provided. The compound has Formula I: wherein W is selected from the group consisting of an optionally substituted aryl group and an optionally substituted heteroaryl group; each Y independently is NR1R2, wherein R1 and R2 are independently selected from the group consisting of H and C1-C6 alkyl, or R1 and R2 combine to form together with the nitrogen to which they are attached a heterocyclic group with 4 to 5 carbon atoms, is used to denote a single or a double bond, and Z is NH, NH2, NH—(C?O)—(CH2)n—SH, wherein n=1 to 10, or or a tautomer or stereoisomer thereof, or a salt thereof. A method and device for detecting an analyte using Surface Enhanced Raman Spectroscopy (SERS) is also provided.
    Type: Application
    Filed: October 12, 2011
    Publication date: May 24, 2012
    Inventors: Young-Tae CHANG, Kaustabh Kumar Maiti, Dinish Unnimadhava Kurup Soudamini Amma, Chit Yaw Fu, Malini Olivo, Kiat Seng Jason Soh, Seong-Wook Yun
  • Publication number: 20120122966
    Abstract: An organic dye from the group of crystal violet, gentian violet, malachite green oxalate and rhodamine 6G used as an analgesic agent in the form of a solution with the agent dosage ranging from 0.000001 mg to 10 g per intake. It is preferable to take the agent at least two times a day. In particular cases of use the agent is administered by mouth in the form of an aqueous solution before or after meals, or it is administered per rectum in the form of an aqueous solution, or a 1% solution of the agent is administered intravenously, or the agent is used in the form of a 1-5% ointment, or the agent is administered per rectum in the form of suppositories, and when arresting cancer pain the agent is injected into the tumor (under the tumor) or into a metastasis.
    Type: Application
    Filed: April 14, 2009
    Publication date: May 17, 2012
    Inventor: Mikhail Vladimirovich Kutushov
  • Publication number: 20120076848
    Abstract: Methods and systems are described for a rapid and sustainable change in the pigment melanin content of melanocytes of the iris stroma, thereby to change the color of the eye. Also described are nanoparticle compositions for lightening the pigmented tissues or treating a pigmented tissue related disease.
    Type: Application
    Filed: July 21, 2010
    Publication date: March 29, 2012
    Inventor: Kambiz Thomas Moazed
  • Publication number: 20120027844
    Abstract: Compounds and their syntheses are disclosed herein. Compositions and pharmaceutical compositions comprising a compound are also described, and include compositions also comprising liposomes. Methods for the treatment of cancer in animals comprising administering a compound or a composition comprising a compound are also described.
    Type: Application
    Filed: February 9, 2010
    Publication date: February 2, 2012
    Applicants: XAVIER UNIVERSITY OF LOUISIANA, TULANE UNIVERSITY
    Inventors: Barbara S. Beckman, Maryam Foroozesh, Jiawang Liu
  • Patent number: 8097656
    Abstract: This invention is related to new nitrogenated trans-stilbene compounds, more specifically, imine, pyrrole and indole derivatives, with procedures for the preparation and use thereof as pharmaceutical compositions for the treatment and/or chemoprevention of those mammalian diseases such as cancer, fibrosclerosis and acute/chronic inflammation, graft-versus-host reaction, ischemic-reperfusion tissue injury in stroke and heart attack, neurodegeneration, and during organ transplantation, whose pathogenic and pathophysiological mechanisms depend on or are significantly contributed by undesirable oxidative stress, angiogenic and proliferative responses.
    Type: Grant
    Filed: August 23, 2010
    Date of Patent: January 17, 2012
    Assignees: Dominion Pharmakine S.L, Universidad del Pais Vasco
    Inventors: Fernando Pedro Cossio, Eneko Aldaba Arevalo, Yosu Ion Vara Salazar, Aizpea Zubia Olascoaga, Silvia Vivanco Amato, Miren Lorea Mendoza Arteche, Clarisa Salado Pogonza, Natalia Gallot Escobal, Fernando Vidal Vanaclocha
  • Publication number: 20120004314
    Abstract: The invention relates to an antimicrobial composition comprising chlorhexidine and pentane-1,5-diol. Such a composition may be used to combat microorganisms.
    Type: Application
    Filed: July 2, 2009
    Publication date: January 5, 2012
    Applicant: AMBRIA DERMATOLOGY AB
    Inventor: Jan Faergemann
  • Publication number: 20110243854
    Abstract: Methods of treating disorders such as neurofibromatosis-1 are provided, including methods in which catalytic antioxidants such as metalloporphyrins are administered. Methods of regulating longevity, and methods and systems for screening for modulators of aging or longevity, are also provided. In addition, related transgenic animals are described.
    Type: Application
    Filed: October 20, 2010
    Publication date: October 6, 2011
    Applicant: The Regents of the University of California
    Inventors: Douglas C. Wallace, James Jiayuan Tong
  • Publication number: 20110230474
    Abstract: The invention includes a method of treating a mammal comprising topically applying an aqueous composition to a target site on the mammal, wherein the aqueous composition comprises: active ingredients comprising i) a cosmetic dye selected from a violet, blue or green dye, or combinations thereof, and ii) an enhancing ingredient, wherein the relative weight percentage of the cosmetic dye to the enhancing ingredient is about 1:2 to about 40:1, wherein the cosmetic dye interacts with keratinous material thereby i) substantially staining the target site and ii) inhibiting the active ingredients from significantly leaching from the target site.
    Type: Application
    Filed: January 14, 2011
    Publication date: September 22, 2011
    Inventors: Irina Grigorian, Manfred F. Dyck, Rainer Gruening
  • Publication number: 20110060038
    Abstract: This invention is related to new nitrogenated trans-stilbene compounds, more specifically, imine, pyrrole and indole derivatives, with procedures for the preparation and use thereof as pharmaceutical compositions for the treatment and/or chemoprevention of those mammalian diseases such as cancer, fibrosclerosis and acute/chronic inflammation, graft-versus-host reaction, ischemic-reperfusion tissue injury in stroke and heart attack, neurodegeneration, and during organ transplantation, whose pathogenic and pathophysiological mechanisms depend on or are significantly contributed by undesirable oxidative stress, angiogenic and proliferative responses.
    Type: Application
    Filed: August 23, 2010
    Publication date: March 10, 2011
    Applicants: DOMINION PHARMAKINE S.L., UNIVERSIDAD DEL PAIS VASCO
    Inventors: Fernando Pedro Cossio, Eneko Aldaba Arevalo, Yosu Ion Vara Salazar, Aizpea Zubia Olascoaga, Silvia Vivanco Amato, Miren Lorea Mendoza Arteche, Clarisa Salado Pogonza, Natalia Gallot Escobal, Fernando Vidal Vanaclocha
  • Publication number: 20100311673
    Abstract: Sulfanyl-tetrahydropyran-based compounds, pharmaceutical compositions comprising them, and methods of their use for the treatment of diseases and disorders such as diabetes and obesity are disclosed.
    Type: Application
    Filed: August 18, 2010
    Publication date: December 9, 2010
    Inventors: Bryce Alden Harrison, Spencer David Kimball, Ross Mabon, David Brent Rawlins
  • Publication number: 20100278933
    Abstract: The invention relates to kinase inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating disorders, especially cancer.
    Type: Application
    Filed: June 5, 2008
    Publication date: November 4, 2010
    Applicant: University of Florida Research Foundation, Inc
    Inventors: Peter P. Sayeski, György M. Keserü
  • Publication number: 20100280125
    Abstract: Medicine and pharmacology, in particular a medicinal agent exhibiting anti-tumoral and immunomodulatory actions and including a tri-p-amino-thiphenyl-chlormethan tetramethylated, pentamethylated or hexamethylated derivative, the mixtures thereof or the combination thereof with dextrin. The agent of this invention exhibits a high activity and a reduced side effect.
    Type: Application
    Filed: July 12, 2010
    Publication date: November 4, 2010
    Inventor: Mikhail Vladimirovich Kutushov
  • Patent number: 7754700
    Abstract: A composition for alleviating symptoms associated with neurotoxicity. The composition may comprise compounds for preventing glutamate mediated neurotoxicity. The composition may include one or more of the following elements: at least one glutamate antagonist, at least one cAMP stimulating agent, at least one antioxidant, vitamin B12, at least one transporter and at least one surfactant. The composition may be used in methods for alleviating tinnitus, Ménière's Disease and/or hearing loss.
    Type: Grant
    Filed: April 24, 2006
    Date of Patent: July 13, 2010
    Inventor: Seymour F. Trager
  • Patent number: 7732492
    Abstract: The present invention provides a small-sized preparation that is easy to take, containing 26% or more of nateglinide and 28% or more of at least one disintegrant selected from the group consisting of carmellose or salts thereof, sodium carboxymethyl starch, croscarmellose sodium, crospovidone, partly pregelatinized starch and low-substituted hydroxypropyl cellulose, based on the total mass of the preparation. The preparation of the present invention has high contents of nateglinide, which can be absorbed immediately to exhibit a hypoglycemic action.
    Type: Grant
    Filed: February 8, 2006
    Date of Patent: June 8, 2010
    Assignee: Ajinomoto Co., Inc.
    Inventors: Chisato Makino, Erika Motomura, Kunikazu Suzuki, Takahiko Andou, Nobutaka Ninomiya, Akira Yabuki
  • Patent number: 7718705
    Abstract: Methods for the prevention, treatment, or management of sexual dysfunction, such as premature ejaculation, by administering to a patient in need of therapy a therapeutically effective amount of a rapid-onset selective serotonin reuptake inhibitor on an as-needed basis shortly before sexual activity.
    Type: Grant
    Filed: August 22, 2000
    Date of Patent: May 18, 2010
    Assignee: Eli Lilly and Company
    Inventor: Karl Bruce Thor
  • Patent number: 7709533
    Abstract: The present invention provides a class of chemical compounds useful in the treatment of sickle cell disease, diseases characterized by unwanted or abnormal cell proliferation and for the treatment of ocular disorders such as glaucoma. The active compounds are tri-(aryl or heteroaryl) methane compounds or analogues thereof which further comprise an imine moiety and where the tertiary carbon atom can be replaced with a different atom such as Si, Ge, N or P. The compounds enhance resistance to degradation in a biological medium, inhibit potassium flux in a cell, reduce mammalian cell proliferation, reduce the Gardos channel of erythrocytes, reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation.
    Type: Grant
    Filed: February 1, 2006
    Date of Patent: May 4, 2010
    Assignee: Icagen, Inc.
    Inventors: Xiaodong Wang, Alan Bradley Fulp, Darrick Seconi
  • Publication number: 20100099742
    Abstract: The invention refers to the use of a cytokine antagonist which modulates the expression and/or the function of a cytokine, particularly a Th2 helper cell cytokine, in a cell and causes the down-regulation of anti-apoptotic proteins in said cell through the cytokine modulation for sensitizing cells for apoptosis. In particular, the cells that can be treated with the cytokine antagonists are drug-resistant cancer cells which fail to undergo apoptosis.
    Type: Application
    Filed: November 30, 2009
    Publication date: April 22, 2010
    Inventors: Giorgio Stassi, Matilde Todaro